Guardant Health Inc

Guardant Health, Inc. is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in 2012 and is headquartered in Palo Alto, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Guardant Health reports robust Q1 earnings, eyes growth opportunities

Guardant Health's Q1 2023 earnings call showcased strong financial performance, advancements in screening technology, and a focus on operational efficiency. The company's revenue growth, successful Medicare reimbursement, and strategic guidance raise optimism for future growth. Challenges lie in managing expenses and commercial investments post-FDA approval.

Guardant Health reports robust Q2 results and eyes international expansion

Guardant Health's Q2 performance reflects strong revenue growth and test volume increase, with a focus on achieving cash flow breakeven.
The company's strengths lie in expanding payer coverage, advancing Shield blood tests, and seeing growth in the MRD market.
Challenges include legal expenses, low lung cancer screening rates, and managing cash burn, while opportunities exist in Japan market expansion and EMR integration.
Overall, Guardant Health is poised for growth with a strategic focus on innovation, market expansion, and financial sustainability.

Guardant Health reports strong Q3 performance, eyes international expansion

Guardant Health's Q3 2023 showcased robust revenue growth and strong test volume performance, particularly in Precision Oncology and Guardant360.
The company's focus on innovation, payer coverage breakthroughs, and international expansion presents significant growth opportunities.
While Shield V2 faces challenges in AA detection, progress on FDA approval and sales strategy post-approval are key areas of focus.
Overall, Guardant Health's strategic investments and product advancements position it well for continued growth and market leadership.

Guardant Health reports robust revenue growth and strategic advancements

Guardant Health's strong financial performance, focus on key strengths, and management of challenges position the company for continued growth
Opportunities in revenue growth, product upgrades, and market expansion present avenues for further success
Strategic initiatives in therapy selection, MRD, and screening underscore Guardant Health's commitment to innovation and market leadership

Guardant Health excels in Q2 2024 with FDA-approved Shield test

Guardant Health's Q2 2024 performance showcased strong revenue growth, driven by the success of the Shield blood test and Guardant360. While facing challenges in cash flow, the company remains optimistic about future opportunities in the diagnostic testing market.

Guardant Health reports robust Q3 earnings, eyes international expansion

Guardant Health's Q3 2024 earnings call highlighted strong revenue growth, exceeding expectations in key segments. The company raised its full-year revenue guidance and showcased improvements in free cash flow. Shield blood test and Reveal revenue are expected to drive future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Guardant Health, Inc. is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in 2011 and is headquartered in Palo Alto, CA.

Guardant Health: Due For A Rally

Findings Consistent with Suboptimal Genotyping Rates in Metastatic Lung Cancer Findings Consistent with Suboptimal Genotyping Rates in Metastatic Lung Cancer

Study Shows Only 40 Percent of Patients with Metastatic Colon Cancer Receive Guideline-Recommended Biomarker Testing

Hibbett Sports

Just Energy Group

Unique Fabricating

Top Ranked Momentum Stocks to Buy for December 6th

Guardant Health (NASDAQ:GH) offers non-invasive cancer diagnosis tests and is based out of the U.S. The company has seen its stock rally 15% since its Q3 results were announced.

Strong Q3 Results Drive Guardant’s Stock 15% Higher In 20 Days

The diagnostic company reported third-quarter 2019 operating results.

Here's Why Guardant Health Gained 11.8% in November

Exact Sciences

Guardant Health (blood-based liquid biopsies) and Exact Sciences (stool-based colorectal cancer detection) have both announced plans to compete directly in each other's core market.

High Growth Non-Invasive Cancer Test Technology: Guardant Health Vs. Exact Sciences

Costco

O'Reilly Automotive

Children's Place

Rush Enterprises

CNBC combed through recent Wall Street research to find stocks analysts say are "best in class."

These stocks are "best in class" according to Wall Street analysts

GEO Group

Since Elizabeth Warren made her prison policy pitch, shares in two prison REITs have lost around one-third of their value since June 2019.

2 Prison REITs Poised To Profit

Kirkland Lake Gold

Target

These stocks are currently witnessing short-term pullback in a bull market. So, this could just be the perfect entry point for investors who are looking to enhance their portfolio returns.

Top 3 Momentum Anomaly Stocks to Buy for Healthy Profits

The company has a new way to treat cancer patients, and its stock price has doubled this year. But its best days may still be ahead.

3 Great Reasons to Buy Guardant Health

As of late, it has definitely been a great time to be an investor Guardant Health.

Guardant Health Shares March Higher, Can It Continue?

DexCom

Insulet

Guardant, Dexcom, and Insulet nailed their quarters and have massive room to grow in the long run, too.

3 Medtech Earnings Winners

Guardant Health Inc (GH) CEO Helmy Eltoukhy on Q3 2019 - Earnings Call Transcript

There's nothing like triple-digit-percentage sales growth to make investors happy.

Why Guardant Health Shares Jumped 12% Today

CRISPR Therapeutics

Editas Medicine

Illumina

Intellia Therapeutics

Invitae

REGENXBIO

Veracyte

As investors shift out of growth names and to more defensive pockets of the market, market watchers now see these biotech players as undervalued.

8 Undervalued Biotech Stocks to Watch Now

During Guardant Health's (GH) Q3 conference call, investors will watch out for the latest news on the colorectal cancer screening rates of its LUNAR-2 blood test.

Guardant Health (GH) to Report Q3 Earnings: What's in Store?

MongoDB

Trade Desk

These stocks each have three secret ingredients for long-term investing success.

3 Stocks That Could Make You Rich: GH, MDB & TTD

Livongo Health Inc

Masimo

These three healthcare pioneers have slid down to nice prices that investors should take advantage of this month.

3 Top Healthcare Stocks to Buy in October

Adaptive Biotechnologies

Personalis Inc

Is Wall Street's initial excitement giving way to more realistic expectations?

Here's Why Liquid Biopsy Stocks Fell as Much as 39.2% in September

Supports Recent Addition of HER2 Blockade Therapy to NCCN Guidelines for Treatment Refractory mCRC Patients Supports Recent Addition of HER2 Blockade Therapy to NCCN Guidelines for Treatment Refractory mCRC Patients

Data Presented at ESMO Show Metastatic CRC Patients with HER2 Amplification Detected by Guardant360 Experience Clinical Benefit After Targeted Therapy

Vertex Pharmaceuticals

Success is in these three great healthcare stocks' DNA.

3 Top Healthcare Stocks - to Buy Right Now

Allakos Inc

Twist Bioscience Corp

Find out why these new healthcare stocks keep climbing, while most of their peers have underwhelmed.

3 Healthcare IPOs From 2018 That Have Already Doubled

Which stock wins in a matchup between a gene sequencing pioneer and a fast-rising liquid biopsy leader?

Better Buy: Illumina vs Guardant Health

Investors worried about a couple of insider trades put pressure on the stock price.

Here's Why Guardant Health Shares Are Sliding Today

Bristol-Myers

Investments in cancer therapies are expected to rise almost $250 billion by 2023, from $150 billion in 2018. Thus, companies that are coming up with innovative methods to cure this malaise are great investment choices.

News for Guardant Health Inc Stock (GH)